At the end of October 2023 our brother Jack was diagnosed with a rare Cancer - a type of Soft Tissue Sarcoma.

What started as a small painless lump on his knee quickly grew and following what was expected to be a routine trip to the GP, Jack was given a life changing diagnosis. Since November Jack has been undergoing rigorous cycles of chemotherapy under the care of the amazing Sarcoma team at UCLH.

From the very beginning, Jack has been intent on creating something positive from the situation. As part of this, Jack set up Transcend Sarcoma along with a close group of friends to raise funds and awareness for the rare sub-type of Soft Tissue Sarcoma from which he suffers, specifically those that are caused by chromosomal translocation mutations. At present there is no effective treatment for translocation related Sarcomas and Jack’s care is focused on extension of life and controlling the spread of this aggressive cancer.

The mission of Transcend has been to spearhead multi-dimensional fundraising events in 2024. All funds raised will be allocated to research projects to understand how translocation mutations develop in order to provide better outcomes for people impacted by this aggressive cancer in the future. Transcend will be working directly with the pathology and oncology specialists at UCLH to ensure all funds raised will have the maximum possible impact.

Jack has been an absolute inspiration to us all over the last 8 months. As his brothers, Lewis and I wanted to set ourselves a challenge to help raise additional funds for Transcend Sarcoma...

Starting on the 25th July 2024, Lewis and I will be completing 7 marathons in 7 days. We will complete the first 6 marathons up in York before travelling down to London to complete the final marathon ahead of Jack's 34th birthday.

We will be posting daily updates on Transcend Sarcoma's Instagram page once the challenge kicks off. Be sure to give them a follow to keep up to date with the challenge and also to hear about some incredible upcoming events to raise further funds for Translocation Sarcoma research.

Mark & Lewis